MedTrace Logo

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

NCT03349840 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2020-06-09

No results posted yet for this study

Summary

This is a study to be performed in Qatar that will look at the comparison of glycemic control in patients with type 2 diabetes on insulin glargine U100 with insulin degludec over the Ramadan period, to determine whether better glycemic control with fewer hypoglycemic episodes can be achieved.

Conditions

  • Type2 Diabetes

Interventions

DRUG

Insulin Degludec U100

Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin

DRUG

Insulin Glargine

Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Weill Cornell Medical College in Qatar

    lead OTHER

Principal Investigators

  • Stephen Atkin, MD · Weill Cornell Medicine Qatar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-07
Primary Completion
2018-08-03
Completion
2018-12-31

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03349840 on ClinicalTrials.gov